Earkart Limited made a major global impact at the world’s largest otolaryngology conference, held in Indianapolis, USA, from October 11–13, 2025, where the company unveiled its next-generation OMNI platform — a remote diagnostic solution redefining accessibility to expert ENT care worldwide.
The event brought together more than 5,000 ENT specialists, audiologists, researchers, and healthcare leaders from over 75 countries to explore the latest innovations in ENT and audiology care. Earkart’s live demonstrations of OMNI’s real-time precision diagnostics and remote consultation features drew strong interest from global practitioners.
Delegates experienced hands-on interaction with OMNI’s intuitive interface designed to eliminate traditional diagnostic barriers and enhance efficiency in ear healthcare. According to Earkart, multiple leading specialists have already expressed intent to adopt the platform after witnessing its practical application and ease of integration.
Management Commentary
“OMNI empowers specialists to serve patients with precision, wherever they are. This global recognition validates our commitment to advancing intelligent, accessible ENT diagnostics,” said an Earkart spokesperson.
The company stated that OMNI is poised to drive the next wave of digital health adoption across North America, Europe, the Middle East, and emerging healthcare markets, strengthening Earkart’s mission to make intelligent and affordable ENT care accessible globally.
Company Overview
Earkart is a technology-driven hearing healthcare solutions provider, manufacturing modern hearing aids and related devices under the EQFY, Fame, and Radius brands. The company maintains ISO 13485, CDSCO, and BIS certifications, operates 49 Shop-in-Shop clinics across 22 cities, and runs a 4,500 sq. ft. production facility in Noida.
With a 69% government and 29% private revenue mix, Earkart supplies through GeM and ALIMCO platforms, combining social impact with technological innovation in hearing care.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
